How are Parkinson’s patients going to use them early? What do you need to know?
Parkinson ‘ s disease is a progressive disease, initially controlled by drugs, and 70 per cent of patients are well equipped with drugs to control tremors and rigidity.
In terms of drug treatment, these are common drugs:
The first is a left doppa, the most effective drug for Parkinson’s disease at present, with efficiency of up to 75 per cent or more.
The second category is the dopamine receptor agonist, which is used in combination with a left-turned dop, which reduces the use of left-turned dop, as well as secondary reactions, and significantly increases the efficacy of the treatment.
The third is anticholine. For people with high tremors, younger patients can use them.
The fourth is a gastro-methyl transferase inhibitor for chlorophenol. Use alone is ineffective and needs to be combined with enzydomamine, etc., which can increase the efficacy of treatment and reduce the volatility of symptoms.
The fifth is type b of single oxidation inhibitor, for example, Slygilan, which is a good effect.
With regard to the choice of medicines, attention needs to be paid to:
1. Drug treatment as early as possible
In the event of Parkinson ‘ s symptoms, the medication should not be delayed for fear of complications. The treatment can improve motor symptoms such as tremors, rigidity and slowness. It also eases anxiety and provides conditions for rehabilitation training. With regard to drug complications, it was possible to avoid them by regulating them.
2. Treatment varies according to age
There are several reasons why age can be considered an important factor in determining when and how treatment begins. First, while the symptoms of young patients may be more severe, young patients tend to be more benign and intellectually better than older patients. In addition, young patients are often expected to be treated for more than 20 years, so for long-term treatment purposes, the first consideration in choosing medication is to avoid, as far as possible, the long-term application of the adverse effects of vortex doba and to enhance neuro-protective treatment to avoid further disease. On the contrary, as older patients are older, less consideration is given to neuro-protection and the long-term use of left-turned dobas for complications. For patients with pre-60 disease, receptor agonists, do not use dopamine formulations to the extent possible, and for patients with post-60 disease, dopamine formulations are applied appropriately.
3. Dosages vary from person to person
Patients take medications for long periods of time, regularly on a daily basis, and do not suddenly stop. Since Circum-Tropopa is not a drug for treatment of the cause of the disease, but rather an alternative treatment for the improvement of symptoms, with the potential for side effects, it is argued that, with minimal side effects and maximum improvement of the patient’s ability to live, the lower the level of maintenance, often referred to as “square flow”, is less effective.
However, there is a misunderstanding among many about “the lower the better the better” and, regardless of the condition, it is only half a medobar, three times a day, and even many patients are still at the end of the day low-dose left-turn doppelga. Actually, this “low dose” is not absolute, but relative. For Medoba, one and a half a day at an early stage could control symptoms, and three pieces would be unnecessary. But in the middle and end of the year, even three doppelga might not work, with four, and the minimum daily dose would be four, and five would be unnecessary. This is the so-called “drop-down” method, which increases by one drop, to a dose where the symptoms have improved significantly but no significant side effects. In short, medications need to be “sublime, not fully effective”, i.e., dosages are as small as possible and are used regularly over time, with an effect of around 80 per cent.
4. Different categories
In some cases, the most visible dopamine formulations are selected from the onset of the drug, and the effects of this type of drug are clear, but they may lead to an early emergence of side effects. Thus, for younger early patients, dopamine agonists, etc., should be selected, which, while less effective and with obvious side effects, can delay the emergence of drug side effects; for older early patients, dop-type drugs can be used. If the symptoms of tremors are more apparent, antán may be taken for young patients, but it may not be appropriate for older patients, it can be impaired in cognitive terms and can cause hallucinations, and therefore can be used as a left-turned doba formulation. The principle of choice of drugs is to choose a simple and effective drug, with first-line drugs, so that no second or third-line drugs are used to pursue new drugs blindly. Almost all of the new drugs are currently used as auxiliary to the left doppelga formulation, i.e. no single new drug can be used to control the symptoms of Parkinson’s disease, and left doppelga is the gold standard for Parkinson’s disease.
